Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Maxcitracon Nov 01, 2024 1:38pm
270 Views
Post# 36292640

RE:Preliminary Breakthrough Therapy Designation (BTD) Advice

RE:Preliminary Breakthrough Therapy Designation (BTD) Advice
Eoganacht wrote: The FDA BTD FAQ site makes it clear that preliminary BTD advice is advisory and does not predict the actual BTD decision.

Frequently Asked Questions: Breakthrough Therapies


Question 22. What are the timelines for FDA to respond to a breakthrough therapy designation request? 
 
FDA will respond to breakthrough therapy designation requests within 60 days of receipt of the request. 

Question 23. Can a sponsor get preliminary breakthrough therapy designation (BTD) advice from the review division prior to the submission of a formal BTD request?
 
A sponsor can contact the regulatory project manager (RPM) in the division to which the active IND is assigned and request the “Preliminary Breakthrough Therapy Designation (BTD) Advice Request” template. This template should then be submitted as a formal amendment to the IND and a subsequent teleconference between the sponsor and the review division will be set-up by the RPM. The review division will make a recommendation as to whether a request for a BTD is appropriate, may be too preliminary, or does not currently meet the criteria for a BTD. The Agency’s recommendation is advisory and is not to be interpreted to predict the Agency’s decision on the BTD request. NOTE: A Preliminary BTD Advice Request may be submitted to an active PIND, although a formal BTD request may not be submitted until the IND is opened.

Very good point Eoganacht, I like the highlited part that say's  or does not currently meet the criteria for BTD.
Please correct me if I am wrong, but what it does imply is, if all the necessary criterias for the BTD approval are not included in the Pre-BTD application,TLT could have to refile a new Pre-BTD application with the missing informations.

My point is if all the criterias for the Pre-BTD approval have been provided to the review division, then in order to help the SP, TLT could say it in a news release or in an update, as long as the FDA laws permit it naturally.

<< Previous
Bullboard Posts
Next >>